Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chosa Oncology ABXSAT:CHOSA +3.55%32 14-Day RSI is 53.80 as of Jul. 21, 2026. GuruFocus rates XSAT:CHOSA with a GF Score™ of 32/100. Among 1,424 Biotechnology companies, Chosa Oncology AB ranks worse than 78.72% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The industry rank for Chosa Oncology AB's 14-Day RSI or its related term are showing as below:
XSAT:CHOSA's 14-Day RSI is ranked worse than 78.72% of 1424
companies
in the Biotechnology industry
Industry Median: 44.785
vs XSAT:CHOSA: 53.80
Chosa Oncology AB (XSAT:CHOSA) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Chosa Oncology AB 14-Day RSI Related Terms
XSAT:CHOSA vs VRTX, REGN, ALNY: 14-Day RSI Comparison
For the Biotechnology subindustry, Chosa Oncology AB's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chosa Oncology AB 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chosa Oncology AB's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Chosa Oncology AB's 14-Day RSI falls into.
Chosa Oncology AB (XSAT:CHOSA) 14-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chosa Oncology AB (XSAT:CHOSA) has a 14-Day RSI of 53.80 as of Jul. 21, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Chosa Oncology AB and its competitors. According to the industry distribution chart, Chosa Oncology AB ranks #1121 out of 1424 companies in the Biotechnology industry, placing it in the top 78.7%.
Is Chosa Oncology AB's 14-Day RSI too high?
Chosa Oncology AB's current 14-Day RSI is 53.80. The Biotechnology industry median 14-Day RSI is 44.79. Chosa Oncology AB's value of 53.80 is 20.1% above this industry median. Based on the distribution chart, Chosa Oncology AB ranks #1121 out of 1424 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Chosa Oncology AB has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Chosa Oncology AB's 14-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chosa Oncology AB ranks #1121 out of 1424 companies for 14-Day RSI. This places Chosa Oncology AB in the lower half of its industry. The industry median 14-Day RSI is 44.79. Chosa Oncology AB's value of 53.80 is 20.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 44.79, based on 1,424 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chosa Oncology AB's current 14-Day RSI of 53.80 is 20.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Chosa Oncology AB and its competitors. For the Biotechnology industry, the median 14-Day RSI is 44.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chosa Oncology AB's current 14-Day RSI is 53.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chosa Oncology AB stock overvalued right now?
Chosa Oncology AB (XSAT:CHOSA) has a current 14-Day RSI of 53.80. The current 14-Day RSI is 53.80 and 20.1% above the Biotechnology industry median of 44.79. Chosa Oncology AB's overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Chosa Oncology AB (XSAT:CHOSA), the current 14-Day RSI is 53.80 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:CHOSA has been successfully added to your 
